Fidelity-oriented fluorescence imaging probes for beta-galactosidase: From accurate diagnosis to precise treatment

Biotechnol Adv. 2023 Nov:68:108244. doi: 10.1016/j.biotechadv.2023.108244. Epub 2023 Aug 29.

Abstract

Beta-galactosidase (β-gal), a typical glycosidase catalyzing the hydrolysis of glycosidic bonds, is regarded as a vital biomarker for cell senescence and cancer occurrence. Given the advantages of high spatiotemporal resolution, high sensitivity, non-invasiveness, and being free of ionizing radiations, fluorescent imaging technology provides an excellent choice for in vivo imaging of β-gal. In this review, we detail the representative biotech advances of fluorescence imaging probes for β-gal bearing diverse fidelity-oriented improvements to elucidate their future potential in preclinical research and clinical application. Next, we propose the comprehensive design strategies of imaging probes for β-gal with respect of high fidelity. Considering the systematic implementation approaches, a range of high-fidelity imaging-guided theragnostic are adopted for the individual β-gal-associated biological scenarios. Finally, current challenges and future trends are proposed to promote the next development of imaging agents for individual and specific application scenarios.

Keywords: Biotech; Fluorescence imaging; High fidelity; Senescence; β-Galactosidase.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cellular Senescence*
  • Coloring Agents
  • Glycoside Hydrolases
  • Optical Imaging*
  • beta-Galactosidase

Substances

  • beta-Galactosidase
  • Coloring Agents
  • Glycoside Hydrolases